1. Herbal medicines – they are popular, but are they also safe?

   • Edzard Ernst

   Editorial 10 December 2005 Pages: 1 - 2

2. Impact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndrome

   • Amr El-Husseini
   • Fathy El-Basuony
   • Mohamed Sobh

   Clinical Trials 23 December 2005 Pages: 3 - 8

3. Effect of pravastatin on plasma sterols and oxysterols in men

   • Karin M. Thelen
   • Dieter Lütjohann
   • Reijo Laaksonen

   Clinical Trials 30 December 2005 Pages: 9 - 14

4. Cervical cancer and CYP2E1 polymorphisms: implications for molecular epidemiology

   • Paula M. Ferreira
   • Raquel Catarino
   • Rui Medeiros

   Pharmacogenetics 22 December 2005 Pages: 15 - 21

   

5. Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy

   • Keiji Takata
   • Junji Saruwatari
   • Kazuko Nakagawa

   Pharmacogenetics 30 December 2005 Pages: 23 - 28

6. The extent of induction of CYP3A by St. John’s wort varies among products and is linked to hyperforin dose

   • Silke C. Mueller
   • Jolanta Majcher-Peszynska
   • Bernd Drewelow

   Pharmacokinetics and Disposition 10 December 2005 Pages: 29 - 36

   

7. Safety implications regarding use of phytomedicines

   • Laura Cuzzolin
   • Silvana Zaffani
   • Giuseppina Benoni

   Pharmacoepidemiology and Prescription 03 December 2005 Pages: 37 - 42

8. Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction

   • Lars Bjerrum
   • Morten Andersen
   • Jesper Hallas

   Pharmacoepidemiology and Prescription 06 December 2005 Pages: 43 - 49

9. The gap between evidence-based medicine and daily practice in the management of paediatric asthma. A pharmacy-based population study from The Netherlands

   • Tjalling W. de Vries
   • Hilde Tobi
   • Lolkje T. W. de Jong-van den Berg

   Pharmacoepidemiology and Prescription 20 December 2005 Pages: 51 - 55

10. Improving the performance of Drug and Therapeutics Committees in hospitals – a quasi-experimental study in Laos

    • Chu Vang
    • Goran Tomson
    • Rolf Wahlstrom

    Pharmacoepidemiology and Prescription 22 December 2005 Pages: 57 - 63

    

11. Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms

    • Alberto Pilotto
    • Marilisa Franceschi
    • F.I.R.I. (Fondazione Italiana Ricerca Invecchiamento) and the SOFIA Project Investigators

    Pharmacoepidemiology and Prescription 30 December 2005 Pages: 65 - 73

    

12. CYP2D6 polymorphism, tramadol pharmacokinetics and pupillary response

    • Ondřej Slanař
    • Milan Nobilis
    • František Perlík

    Letter to the Editors 08 November 2005 Pages: 75 - 76

    

13. Impact of the CYP2D6 metaboliser status on the pupillary response of tramadol—a commentary

    • Frank Fliegert
    • Burkhard Kurth
    • Karin Göhler

    Letter to the Editor 03 December 2005 Pages: 77 - 78

    

14. Response to Naunton and Duyvendak re “Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?”

    • Lara Monesi
    • Fausto Avanzini
    • Maria Carla Roncaglioni

    Letter to the Editor 01 December 2005 Pages: 79 - 80

15. Underuse of antiplatelets and inappropriate use

    • Mark Naunton
    • Michiel Duyvendak

    Letter to the Editors 01 December 2005 Pages: 81 - 82

16. Evaluation of the effect of multiple-dose administration of R411, a dual α4β1–α4β7 integrin antagonist on the major CYP isoform activities in healthy volunteers

    • Youssef Hijazi
    • Horst Welker
    • Indravadan Patel

    Letter to the Editors 21 December 2005 Pages: 83 - 85

    

17. Treatment of chorea with levetiracetam

    • Theresa A. Zesiewicz
    • Amit Pathak
    • Robert A. Hauser

    Letter to the Editor 01 December 2005 Pages: 87 - 87